NetworkNewsBreaks

FridayMay 12, 2017 12:59 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 12, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: RELV 22.58% – News: Posts Q1 sales of $12.8M, swings to profit PME 17.16% – News: Signs framework agreement to supply deep ocean fish products to supermarket and restaurant in China CPRX 5.98% – News: Receives a 2017 Beacon Award for industry in the Life Sciences & Healthcare category HEAR 5.95% – News: Will present at 18th Annual B. Riley & Co. Institutional Investor Conference on May 25 FORK 5.47% – News: Q1 net…

Continue Reading

FridayMay 12, 2017 12:58 pm

NetworkNewsBreaks – Capricor Therapeutics’ (NASDAQ: CAPR) ALLSTAR Trial Update Triggers Sell-off; Company to Focus on DMD, Trim Workforce

Shares of Capricor Therapeutics (NASDAQ: CAPR) dropped to a new 52-week low this morning – currently trading at $1.23 per share - after the company announced that six-month data of its ALLSTAR Trial demonstrated a low probability of achieving a statistically significant difference in its primary efficacy endpoint. "The lack of a clear difference in the change in scar size from baseline to six months between the active and control groups in the interim observations from ALLSTAR was unexpected. These results diverge from the consistent and extensive record of activity observed with our cell technology in the setting of cardiac…

Continue Reading

FridayMay 12, 2017 12:56 pm

NetworkNewsBreaks – Celsion Corporation (NASDAQ: CLSN) Shares Higher following Q1 Results, Development Program Update

Celsion Corporation (NASDAQ: CLSN) this morning posted its first-quarter results and issued an update on its lead program for ThemoDox®, currently in separate clinical trials for the treatment of primary liver cancer and recurrent chest wall breast cancer. Celsion’s immunotherapy program consists of GEN-1, currently in phase I development for the localized treatment of ovarian cancer. "Celsion continues to make major progress with respect to our ongoing global, pivotal Phase III OPTIMA Study in primary liver cancer.  This ground-breaking study continues to attract interest and support from the medical community, international regulatory agencies, and research organizations like the National Institutes…

Continue Reading

FridayMay 12, 2017 12:07 pm

NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses Acquisition Strategy in Interview on MoneyTV

Specialized holding company SinglePoint, Inc. (OTC: SING) is a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” To view the show, visit www.MoneyTV.net. In this week’s episode, SinglePoint CEO Greg Lambrecht discusses the company’s progress toward expanding its presence in the burgeoning legal marijuana industry by way of acquisition. “We’ve spent the last couple of months courting companies to acquire them, particularly in the cannabis space,” Lambrecht noted in the interview. “Actually, I think next week we’re going to be putting an LOI…

Continue Reading

FridayMay 12, 2017 11:08 am

NetworkNewsBreaks – Trevena, Inc. (NASDAQ: TRVN) Has “Buy” Rating Reiterated by Aegis Capital

Trevena (NASDAQ: TRVN) is reiterated with a ‘Buy’ rating and $14 price target by Aegis Capital Corp. following the biopharmaceutical company’s report of financial results for the quarter ended March 31, 2017. Trevena reported cash, cash equivalents, and marketable securities at $97.9 million as of March 31, 2017. Trevena expects its cash on hand will fund operations into the third quarter of 2018. This includes funding enrollment in the phase 3 ATHENA study by mid-year adequate to support the submission of the NDA for OLINVO, submitting the NDA to the FDA in the fourth quarter of 2017, advancing TRV250 through…

Continue Reading

FridayMay 12, 2017 11:06 am

NetworkNewsBreaks – Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) Receives Reiterated “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and a price target of $11 on shares of Conatus Pharmaceuticals (NASDAQ: CNAT) after the company reported first quarter 2017 financial results. The company reported total revenues of $7.0 million and cash, cash equivalents and marketable securities of $80.5 million at the end of the first quarter. Among other highlights, the analyst noted that the company said Novartis has exercised its exclusive license option for the global development and commercialization of emricasan, which will become effective after Conatus receives a $7 million payment from Novartis. The payment is expected in mid-2017. For more information,…

Continue Reading

ThursdayMay 11, 2017 12:54 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 11, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MSLI 56.11% – News: Enters definitive agreement with Norgine B.V. SNBP 40.00% – News: Posts Q1 2017 financial results GCFB 20.00% – News: Names new CEO SLTK 12.20% – News: Participating in the Marijuana Business Conference & Expo May 17-19 FNCX 10.75% – News: Amends the terms of binding term sheet to acquire BumpClick LLC NVAX 7.85% – News: Appoints VP, clinical development and translational medicine MRMD 6.90% – News: Acquires MariMed Advisors, changes…

Continue Reading

ThursdayMay 11, 2017 12:53 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Zogenix, Inc. (NASDAQ: ZGNX)

Following Zogenix’s (NASDAQ: ZGNX) first-quarter results, Aegis Capital has reiterated its ‘Buy’ rating and price target of $28 on shares of the company’s stock. Zogenix reported total revenue for the first quarter of $2.7 million, consisting entirely of contract manufacturing revenue. Additionally, Zogenix recently said it has completed enrollment in Study 1, the first phase 3 clinical trial evaluating ZX008 as an adjunctive treatment for seizures in children and young adults with Dravet syndrome. Top-line data from Study 1 is anticipated in the third quarter of 2017. The company is currently enrolling for 1504, the second pivotal phase 3 trial in…

Continue Reading

ThursdayMay 11, 2017 12:52 pm

NetworkNewsBreaks – Aegis Capital Issues “Buy” Rating on CytoSorbents Corp. (NASDAQ: CTSO)

Aegis Capital has issued a ‘Buy’ rating and price target of $9 on CytoSorbents Corp. (NASDAQ: CTSO) following the company’s report of financial and operational results for the quarter ended March 31, 2017. The company reported total revenues of $3.1 million for the first quarter of 2017, which includes both product sales and grant income. This represents an increase of 72% from revenues of $1.8 million from the same period of the previous year. The analyst noted the company’s plan to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval of its flagship CytoSorb® blood filter as well as plans to expand…

Continue Reading

ThursdayMay 11, 2017 12:50 pm

NetworkNewsBreaks – Synthesis Energy Systems, Inc. (NASDAQ: SYMX) Locks In Technology License Agreement for Project in Australia; Shares Climb

Synthesis Energy Systems (“SES”) (NASDAQ: SYMX) shares ticked 8% higher after the company said it has entered into a definitive Technology License Agreement with Australian Future Energy Pty Ltd ("AFE") for a large-scale project to be located in Australia. Per the agreement, SES will collect fees based on the licensed capacity for the project, and for the Process Design Package (PDP), totaling $27 million. Additionally, the entire package of technology, services and equipment is anticipated to provide SES with revenue of approximately $150 million. The company will immediately begin providing technical services to AFE related to the development of the…

Continue Reading